Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 127Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Myelodysplastic Syndromes 25Leukemia 25Burkitt Lymphoma 25Leukemia, Biphenotypic, Acute 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Mantle-Cell 14Recurrence 13Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 10Myeloproliferative Disorders 9Lymphoma 9Lymphoma, Non-Hodgkin 8Leukemia, Myelomonocytic, Chronic 8Lymphoma, Large B-Cell, Diffuse 7Down Syndrome 6Neoplasm, Residual 5Hodgkin Disease 5Blast Crisis 5Sarcoma, Myeloid 4Lymphoma, T-Cell 4Leukemia, Monocytic, Acute 4Hematologic Neoplasms 4Lymphoma, Follicular 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Myelomonocytic, Acute 3Leukemia, Myeloid, Accelerated Phase 3Neoplasms 2Multiple Myeloma 2Lymphoma, B-Cell 2

Interventions

Cyclophosphamide 7Etoposide 5Prednisone 4Doxorubicin 4Vincristine 3romidepsin 2pembrolizumab 2etoposide phosphate 2duvelisib 2Melphalan 2Brentuximab Vedotin 2Azacitidine 210-propargyl-10-deazaaminopterin 2tazemetostat 1sodium-iodide symporter 1ruxolitinib 1prednylidene 1glofitamab 1fludarabine phosphate 1fludarabine 1deltacortene 1cemiplimab 1brincidofovir 1belinostat 1X-Rays 1Whole-Body Irradiation 1Valganciclovir 1Therapeutics 1Tacrolimus 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × Cytarabine × 1 year × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡